Invitation to Alligator Bioscience’s earnings call on 23 October 2025
Lund, Sweden – Alligator Bioscience (Nasdaq Stockholm: ATORX), a clinical-stage biotechnology company developing tumor-directed immuno ...
REACtiVe-2 Phase 1 data featuring mitazalimab demonstrate immune activation in metastatic pancreatic cancer – to be presented at ESMO 2025
Lund, Sweden – 13 October 2025 – Alligator Bioscience (Nasdaq Stockholm: ATORX), a clinical-stage biotechnology company developi ...
Alligator announces publication of OPTIMIZE-1 biomarker analysis in Cell Reports Medicine supporting mitazalimab and mFOLFIRINOX in metastatic pancreatic cancer
Lund, Sweden – 8 October 2025 – Alligator Bioscience (Nasdaq Stockholm: ATORX), a clinical-stage biotechnology company developin ...
Alligator Bioscience announces acceptance of two abstracts at SITC 40th Anniversary Annual Meeting
Lund, Sweden – 6 October 2025 – Alligator Bioscience (Nasdaq Stockholm: ATORX), a clinical-stage biotechnology company developin ...
Change in number of shares and votes in Alligator Bioscience AB
During September 2025, the number of shares and votes in Alligator Bioscience AB (“Alligator Bioscience”) has increased as a res ...
Alligator announces final 30-month OPTIMIZE-1 results highlighting the potential of mitazalimab in metastatic pancreatic cancer
Lund, Sweden – 22 September 2025 – Alligator Bioscience (Nasdaq Stockholm: ATORX), a clinical-stage biotechnology company develo ...
Alligator Bioscience AB announces final outcome of exercise of warrants series TO 13
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, CANADA, HONG KONG, J ...
Alligator Bioscience AB announces preliminary outcome of exercise of warrants series TO 13
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, CANADA, HONG KONG, J ...
Alligator to present new preclinical results on ATOR-4066 at CICON25
Lund, Sweden – 12 September 2025 – Alligator Bioscience (Nasdaq Stockholm: ATORX), a clinical-stage biotechnology company develo ...